The value of a stake held by Malin, the Dublin-based biotech investment fund, in a US drug company has fallen by almost €35 million, amid the halting of a safety trial for a prostrate cancer drug due to a patient death.
Malin last week said the value of its 19 per cent stake in Poseida Therapeutics had been marked down to €76.2 million at the end of August, from €110 million at the end of...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team